WallStSmart
TERN

Terns Pharmaceuticals Inc

NASDAQ: TERN · HEALTHCARE · BIOTECHNOLOGY

$52.95
+0.00% today

Updated 2026-05-05

Market cap
$6.12B
P/E ratio
P/S ratio
302.64x
EPS (TTM)
$-1.03
Dividend yield
52W range
$0 – $53
Volume
6.8M

Terns Pharmaceuticals Inc (TERN) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2018201920202021202220232024
Total assets$89.07M$23.90M$92.29M$168.07M$287.03M$268.52M$363.93M
Cash & equivalents$82.52M$12.33M$74.85M$47.70M$143.24M$79.93M$161.44M
Current assets$88.48M$22.22M$90.87M$166.93M$285.19M$267.43M$362.11M
Total liabilities$16.84M$5.58M$23.70M$7.77M$10.08M$13.15M$18.06M
Current liabilities$2.38M$4.95M$22.82M$6.82M$8.47M$11.94M$15.65M
Long-term debt
Shareholder equity$72.23M$4.21M$68.59M$160.30M$276.94M$255.37M$345.87M
Retained earnings$-23.25M$-91.86M$-131.91M$-182.07M$-242.42M$-332.63M$-421.48M
Accounts receivable$12.72M
Inventory$2.97M
Goodwill

Frequently asked questions

What is Terns Pharmaceuticals Inc's revenue?

Terns Pharmaceuticals Inc's trailing twelve-month revenue is $1.00M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does TERN generate?

TERN produced $-82.18M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TERN's balance sheet healthy?

TERN holds $161.44M in cash and equivalents against — in long-term debt, on $345.87M of shareholder equity. That debt is best read against the cash flow the business throws off each year.